(ORI) Old Republic International - Overview
Stock: Insurance, Title, Warranty, Surety, Escrow
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 8.74% |
| Yield on Cost 5y | 27.73% |
| Yield CAGR 5y | -1.67% |
| Payout Consistency | 90.7% |
| Payout Ratio | 106.7% |
| Risk 5d forecast | |
|---|---|
| Volatility | 24.6% |
| Relative Tail Risk | -1.21% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.85 |
| Alpha | 16.37 |
| Character TTM | |
|---|---|
| Beta | 0.421 |
| Beta Downside | 0.514 |
| Drawdowns 3y | |
|---|---|
| Max DD | 13.90% |
| CAGR/Max DD | 1.86 |
Description: ORI Old Republic International January 07, 2026
Old Republic International Corp. (NYSE: ORI) is a diversified insurer headquartered in Chicago, operating primarily in the United States and Canada through two business segments: Specialty Insurance and Title Insurance.
The Specialty Insurance segment underwrites a broad array of property- and casualty-related products-including accident & health, aviation, commercial auto, commercial property, workers’ compensation, and financial indemnity coverages such as errors & omissions and surety-serving corporate, governmental, and institutional clients across transportation, construction, healthcare, education, energy, and financial services.
The Title Insurance segment provides lenders’ and owners’ policies that protect real-estate purchasers and investors, complemented by escrow closing, construction-disbursement services, real-estate information products, and national default-management solutions.
Key recent metrics: 2023 combined ratio of 89.5% (below the industry median of ~92%), indicating underwriting profitability; return on equity (ROE) of 12.4% versus the sector average of ~9%; and a dividend yield of ~3.2% with a 5-year payout growth of 7% per annum, reflecting a stable cash-flow profile.
Sector drivers that materially affect ORI include the U.S. interest-rate environment (which influences investment income and mortgage-related title volumes), the cyclical nature of commercial construction activity (impacting specialty lines), and the broader underwriting cycle that can tighten or loosen pricing discipline across P&C insurers.
For a deeper quantitative view, you may want to explore ORI’s metrics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 936.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 0.17 > 1.0 |
| NWC/Revenue: 33.26% < 20% (prev 25.83%; Δ 7.43% < -1%) |
| CFO/TA 0.04 > 3% & CFO 1.29b > Net Income 936.1m |
| Net Debt (-263.2m) to EBITDA (1.24b): -0.21 < 3 |
| Current Ratio: 134.8 > 1.5 & < 3 |
| Outstanding Shares: last quarter (249.6m) vs 12m ago -0.24% < -2% |
| Gross Margin: 50.35% > 18% (prev 0.63%; Δ 4972 % > 0.5%) |
| Asset Turnover: 31.46% > 50% (prev 29.56%; Δ 1.90% > 0%) |
| Interest Coverage Ratio: 16.88 > 6 (EBITDA TTM 1.24b / Interest Expense TTM 70.1m) |
Altman Z'' 1.85
| A: 0.10 (Total Current Assets 3.05b - Total Current Liabilities 22.6m) / Total Assets 29.92b |
| B: 0.20 (Retained Earnings 6.04b / Total Assets 29.92b) |
| C: 0.04 (EBIT TTM 1.18b / Avg Total Assets 28.88b) |
| D: 0.25 (Book Value of Equity 5.91b / Total Liabilities 24.00b) |
| Altman-Z'' Score: 1.85 = BBB |
What is the price of ORI shares?
Over the past week, the price has changed by +6.64%, over one month by -1.86%, over three months by +9.44% and over the past year by +23.79%.
Is ORI a buy, sell or hold?
- StrongBuy: 0
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ORI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 42.5 | 1.7% |
| Analysts Target Price | 42.5 | 1.7% |
| ValueRay Target Price | 54.5 | 30.6% |
ORI Fundamental Data Overview February 02, 2026
P/S = 1.0609
P/B = 1.6308
P/EG = -0.85
Revenue TTM = 9.09b USD
EBIT TTM = 1.18b USD
EBITDA TTM = 1.24b USD
Long Term Debt = 1.59b USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 1.59b USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = -263.2m USD (from netDebt column, last quarter)
Enterprise Value = 11.02b USD (9.69b + Debt 1.59b - CCE 263.2m)
Interest Coverage Ratio = 16.88 (Ebit TTM 1.18b / Interest Expense TTM 70.1m)
EV/FCF = 8.54x (Enterprise Value 11.02b / FCF TTM 1.29b)
FCF Yield = 11.72% (FCF TTM 1.29b / Enterprise Value 11.02b)
FCF Margin = 14.21% (FCF TTM 1.29b / Revenue TTM 9.09b)
Net Margin = 10.30% (Net Income TTM 936.1m / Revenue TTM 9.09b)
Gross Margin = 50.35% ((Revenue TTM 9.09b - Cost of Revenue TTM 4.51b) / Revenue TTM)
Gross Margin QoQ = 11.98% (prev 64.84%)
Tobins Q-Ratio = 0.37 (Enterprise Value 11.02b / Total Assets 29.92b)
Interest Expense / Debt = 1.09% (Interest Expense 17.4m / Debt 1.59b)
Taxrate = 21.21% (55.8m / 263.1m)
NOPAT = 932.3m (EBIT 1.18b * (1 - 21.21%))
Current Ratio = 134.8 (out of range, set to none) (Total Current Assets 3.05b / Total Current Liabilities 22.6m)
Debt / Equity = 0.27 (Debt 1.59b / totalStockholderEquity, last quarter 5.91b)
Debt / EBITDA = -0.21 (Net Debt -263.2m / EBITDA 1.24b)
Debt / FCF = -0.20 (Net Debt -263.2m / FCF TTM 1.29b)
Total Stockholder Equity = 6.11b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.24% (Net Income 936.1m / Total Assets 29.92b)
RoE = 15.32% (Net Income TTM 936.1m / Total Stockholder Equity 6.11b)
RoCE = 15.37% (EBIT 1.18b / Capital Employed (Equity 6.11b + L.T.Debt 1.59b))
RoIC = 12.01% (NOPAT 932.3m / Invested Capital 7.76b)
WACC = 6.53% (E(9.69b)/V(11.28b) * Re(7.46%) + D(1.59b)/V(11.28b) * Rd(1.09%) * (1-Tc(0.21)))
Discount Rate = 7.46% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -5.11%
[DCF Debug] Terminal Value 83.35% ; FCFF base≈1.24b ; Y1≈1.19b ; Y5≈1.18b
Fair Price DCF = 119.6 (EV 29.25b - Net Debt -263.2m = Equity 29.52b / Shares 246.7m; r=6.53% [WACC]; 5y FCF grow -4.61% → 2.90% )
EPS Correlation: 62.12 | EPS CAGR: 4.38% | SUE: -1.81 | # QB: 0
Revenue Correlation: 52.57 | Revenue CAGR: 1.60% | SUE: 1.78 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.79 | Chg30d=-0.073 | Revisions Net=-1 | Analysts=3
EPS current Year (2026-12-31): EPS=3.30 | Chg30d=-0.233 | Revisions Net=-2 | Growth EPS=+4.8% | Growth Revenue=+8.5%
EPS next Year (2027-12-31): EPS=3.48 | Chg30d=-0.117 | Revisions Net=-1 | Growth EPS=+5.6% | Growth Revenue=+6.9%